{"editorial":{"content_id":"e66f8179-94a3-45d0-bb81-6149641b33fa","slug":"anvisa-sinopep-20261103-35ac85","content_type":"news","title":"巴西Anvisa授予中国Sinopep连云港工厂良好生产规范认证","summary":"巴西国家卫生监督局向中国药企Sinopep-Allsino Biopharmaceutical颁发良好生产规范认证，涵盖其连云港工厂的司美格鲁肽和替尔泊肽原料药生产。","body":"巴西国家卫生监督局（Anvisa）已向中国药企Sinopep-Allsino Biopharmaceutical颁发良好生产规范认证（CBPF），认证范围涵盖该公司位于中国连云港的工业单位，涉及用于司美格鲁肽和替尔泊肽药物的原料药生产。该决定于11月3日（周二）在巴西联邦官方公报上公布。\n\n该认证使这家制造商进入生产单位的生产规范获得巴西卫生当局认可的外国企业行列，具体范围以公布内容为准。\n\n司美格鲁肽和替尔泊肽是用于治疗2型糖尿病和肥胖症的药物中的活性成分，依据各产品获批的适应症。司美格鲁肽作为GLP-1受体激动剂起作用，替尔泊肽则作用于GIP和GLP-1激素受体。两者均与血糖、食欲和饱腹感的调节相关，这些特性扩大了此类治疗药物的需求。\n\n良好生产规范认证证明制造商在生产流程和质量管理方面符合卫生要求。就原料药而言，评估考虑旨在确保生产环节质量和标准化的程序。\n\nAnvisa指出，向Sinopep颁发证书并不等同于在巴西注册新药，也不自动授权销售成品。原料药生产与药品注册属于不同的监管阶段，每款产品须满足适用的卫生要求才能进入巴西市场。","why_it_matters":null,"cbi_observation":null,"direction_tag":"双边","primary_category":"科技平台","secondary_topics":["合规","市场进入","企业动态","br-health"],"content_level":"编辑整理","event_type":"合规认证","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-03T23:03:08.983Z","display_date":"2026-11-03","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/fabricante-de-insumos-da-china-ganha-aval-da-anvisa-para-atuar-no-brasil/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-sinopep-20261103-35ac85","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-sinopep-20261103-35ac85","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-sinopep-20261103-35ac85?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-sinopep-20261103-35ac85?view=json","last_updated":"2026-11-03T23:03:36.043Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}